Target: Brain iron accumulation in neurodegenerative diseases
Approach: Use iron chelators (deferiprone, deferasirox, deferoxamine) to reduce brain iron levels and prevent iron-mediated oxidative damage
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy, Corticobasal Syndrome
Score: 74/100
Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[1]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[2].
Key mechanisms include:
The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[7]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[8].
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 6 | Iron chelation is established in other contexts; repurposing for neurodegeneration |
| Mechanistic Rationale | 9 | Strong evidence for iron's role in oxidative stress and protein aggregation |
| Root-Cause Coverage | 8 | Addresses iron accumulation, a upstream pathological driver |
| Delivery Feasibility | 6 | Some agents cross BBB; deferiprone best brain penetration |
| Safety Plausibility | 6 | Known safety profile but agranulocytosis risk (deferiprone) |
| Combinability | 8 | Works with antioxidants, CoQ10, neuroprotective agents |
| Biomarker Availability | 9 | MRI iron quantification (R2*, SWI), oxidative stress biomarkers |
| De-risking Path | 8 | FAIRPARK trials provide proof-of-concept; existing approved agents |
| Multi-disease Potential | 9 | AD, PD, PSP, CBS, ALS - broad applicability |
| Patient Impact | 7 | Addresses fundamental aging-related pathology |
Total: 74/100
| Risk | Mitigation |
|---|---|
| Agranulocytosis (deferiprone) | Weekly CBC monitoring; dose titration |
| Iron deficiency | Monitor serum ferritin; maintain adequate levels |
| BBB penetration variability | Use brain-penetrant agents; optimize delivery |
| Limited efficacy in advanced disease | Early intervention; patient selection |
Iron chelation for neurodegeneration is being pursued by:
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Target validation | Months 1-3 | MRI iron quantification protocol standardization, patient stratification biomarkers | Research team |
| Lead compound selection | Months 4-6 | Compare deferiprone, deferasirox, novel chelators for brain penetration | Medicinal chemistry |
| In vitro proof-of-concept | Months 6-12 | iPSC neuron testing, dose-response, iron mobilization assays | Preclinical team |
Budget: $2-5M
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Animal efficacy | Months 13-18 | MPTP/6-OHDA PD models, APP/PS1 AD models | In vivo pharmacology |
| GLP toxicology | Months 15-21 | 28-day, 90-day studies with focus on hematological safety | Toxicology |
| Formulation development | Months 18-24 | Brain-penetrant chelator optimization, combination formulation | Pharmaceutical development |
Budget: $8-15M
| Milestone | Timeline | Activities | Lead |
|---|---|---|---|
| Phase 1 | Months 24-30 | First-in-human safety, PK in neurodegeneration patients | Clinical operations |
| Phase 2a | Months 30-42 | Dose-finding, MRI iron reduction endpoints | Clinical development |
| Phase 2b | Months 42-60 | Registrational study in PSP/PD | Clinical development |
Budget: $30-50M (phased)
Martin WR, et al. Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020. ↩︎
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992. ↩︎
Jomova K, et al. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010. ↩︎
Bansal S, et al. Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease. Free Radic Biol Med. 2019. ↩︎
Zhang P, et al. Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction. Oxid Med Cell Longev. 2022. ↩︎
Stockwell BR, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017. ↩︎
Dexter DT, et al. The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease. Mov Disord. 1991. ↩︎
Wang JY, et al. Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study. J Neurol Sci. 2021. ↩︎
Devos D, et al. Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial. Lancet Neurol. 2018. ↩︎
Guldberg HC, et al. Deferasirox (Exjade) crosses the blood-brain barrier and reduces brain iron in a mouse model. Neurobiology of Disease. 2013. ↩︎
Devos D, et al. Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial. Mov Disord. 2022. ↩︎
Weinreb O, et al. Novel iron chelator for Parkinson's disease: from bench to clinic. J Neural Transm. 2013. ↩︎
Moreau C, et al. Brain iron depletion in PSP: a 12-month longitudinal MRI study. Neurology. 2022. ↩︎
Crapper McLachlan DR, et al. Aluminum and other metals in Alzheimer's disease. Environ Geochem Health. 1988. ↩︎
Spindler M, et al. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2019. ↩︎